Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12951 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KDM4EGBA1CARM1PRMT6 | |
| SCHEMBL12449698 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KDM4EGBA1CARM1PRMT6 | |
| SCHEMBL25662587 | 0.88 | HRH3 (0.44) | ALDH1A1KDM4ESIGMAR1HRH3 | |
| SCHEMBL12449658 | 0.88 | KDM4E (0.55) | ALDH1A1KDM4ELMNAHRH3 | |
| SCHEMBL12837 | 0.88 | KDM4E (0.55) | ALDH1A1KDM4ELMNAHRH3 | |
| SCHEMBL12449655 | 0.88 | KDM4E (0.55) | ALDH1A1KDM4ELMNAHRH3 | |
| SCHEMBL12449703 | 0.88 | HRH3 (0.44) | ALDH1A1KDM4ESIGMAR1HRH3 | |
| SCHEMBL12669 | 0.88 | HRH3 (0.44) | ALDH1A1KDM4ESIGMAR1HRH3 | |
| SCHEMBL12607 | 0.87 | ALDH1A1 (0.53) | ALDH1A1KDM4ECARM1PRMT6PRMT1 | |
| SCHEMBL24494832 | 0.83 | ALDH1A1 (0.46) | ALDH1A1KDM4ECARM1PRMT6PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023089052-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS | Samsara Therapeutics Inc. (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-3412663-B1 | NITROGEN-CONTAINING HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021194878-A1 | SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2018119441-A9 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2018140809-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018119441-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119448-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119357-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018102725-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2017030814-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | Arvinas, Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| EP-2499146-B1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-7803836-B2 | Aminophenylsulfonamide derivatives as HIV protease inhibitor | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-09-28 | — | — | US | disclosed |
| US-20080306061-A1 | Aminophenylsulfonamide Derivatives as Hiv Protease Inhibitor | JANSSEN SCIENCES IRELAND UC (IE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | PI4KB, MTOR, PI4KA | ALDH1A1 3185/4885KDM4E 1093/4885GBA1 1418/4885 |
| US-20080306061-A1 | Aminophenylsulfonamide Derivatives as Hiv Protease Inhibitor | DNPEP, NPEPPS, ANPEP | ALDH1A1 3182/4885KDM4E 726/4885GBA1 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.